PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Inflammation and Immune Pharmacology, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, Maryland, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1002/jcph.1697
?:doi
?:hasPublicationType
?:journal
  • Journal of clinical pharmacology
is ?:pmid of
?:pmid
?:pmid
  • 32579707
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.997
?:rankingScore_hIndex
  • 104
is ?:relation_isRelatedTo_publication of
?:title
  • Clinical Pharmacology Considerations for Developing Small-Molecule Treatments for COVID-19.
?:type
?:year
  • 2020

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/32579707>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/32579707>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all